ACB $2.130 (-0.93%)

ACNNF $0.230 (0%)

AERO $1.220 (10.91%)

AGEEF $0.242 (10.13%)

ALEAF $0.520 (5.96%)

AMMJ $0.165 (-2.94%)

APHA $5.270 (1.54%)

ARNA $46.670 (0.85%)

ATT:CNX $0.080 (0%)

ATTBF $0.018 (9.72%)

AUSA:CNX $0.450 (0%)

AUSAF $0.340 (0%)

AVXL $3.300 (4.1%)

BAMM:CNX $0.530 (3.92%)

BBM:CNX $0.145 (3.57%)

BBRRF $0.116 (5.09%)

BE:CNX $0.025 (0%)

BIO:CNX $0.135 (-6.9%)

BLEVF $0.020 (-13.04%)

BLO:CNX $0.830 (3.75%)

BLOZF $0.623 (0.55%)

BUDZ $0.340 (-1.98%)

BXNG $0.261 (-37.8%)

CADMF $0.744 (2025.29%)

CALI:CNX $0.085 (0%)

CANN $0.670 (1.47%)

CARA $17.305 (2.46%)

CBII:CNX $0.125 (-7.41%)

CBIIF $0.096 (-7.58%)

CBWTF $0.566 (0.16%)

CGC $24.890 (2.43%)

CGRW $0.175 (2.94%)

CHOO:CNX $0.205 (7.89%)

CHOOF $0.160 (3.71%)

CNAB $0.155 (-0.96%)

CNBX $0.401 (5.71%)

CNGGF $0.930 (13.41%)

CODI $23.380 (-3.27%)

CPMD $1.500 (0%)

CRBP $7.010 (-1.13%)

CRON $8.550 (5.17%)

CROP:CNX $0.015 (0%)

CRTPF $3.300 (0.68%)

CSI:CNX $0.950 (-16.67%)

CTST $1.180 (0.85%)

CURR $2.700 (-0.74%)

CVSI $1.260 (15.6%)

DIGP $0.090 (0%)

DXBRF $0.177 (2.61%)

EAPH $0.001 (40%)

EAT:CNX $0.040 (0%)

EEVVF $0.144 (0%)

EMHTF $0.262 (4.88%)

EPWCF $0.024 (0%)

EVIO $0.072 (-10.43%)

FFRMF $0.027 (-3.91%)

FFT:CNX $0.040 (14.29%)

FNNZF $0.072 (0.26%)

GGTTF $0.139 (-5.58%)

GLDFF $0.019 (-3.02%)

GLH:CNX $0.025 (25%)

GLNNF $0.042 (-3.08%)

GNBT $0.640 (7.56%)

GRIN:CNX $0.105 (-4.55%)

GRWG $4.620 (0.22%)

GSTR:CNX $0.125 (-10.71%)

GTBIF $10.330 (1.74%)

GTII:CNX $13.510 (2.35%)

GWPH $118.970 (-0.13%)

HEXO $1.620 (-8.99%)

HHPHF $0.023 (4%)

HLSPY $0.726 (0%)

HMLSF $7.464 (0.77%)

HMPPF $0.498 (0%)

HRVOF $0.130 (4.49%)

HSTRF $0.244 (0%)

HUGE:CNX $8.450 (6.29%)

IAN:CNX $2.170 (-2.25%)

IGC $0.700 (-6.67%)

IGXT $0.470 (0%)

IIPR $82.500 (-0.6%)

IMLFF $0.229 (16.15%)

INQD $0.002 (8.75%)

IONC:CNX $0.035 (40%)

IONKF $0.024 (32.78%)

ISOL:CNX $0.220 (-4.35%)

ISOLF $0.166 (-10.54%)

ITHUF $1.660 (-2.92%)

IVITF $0.097 (-3.58%)

JWCAF $0.164 (-2.7%)

KALTF $0.033 (-1.49%)

KBEV:CNX $0.150 (0%)

KBEVF $0.111 (0.91%)

KHRNF $0.840 (2.7%)

KSHB $1.960 (9.5%)

LHS:CNX $0.660 (-1.49%)

LHSIF $0.518 (1.47%)

LOVE:CNX $0.155 (6.9%)

LXLLF $0.380 (0%)

LXRP $0.514 (2.8%)

LXX:CNX $0.650 (3.17%)

MCIG $0.048 (116.74%)

MDCL $3.000 (0%)

MEDIF $3.080 (-1.91%)

MGWFF $0.045 (0%)

MICWF $0.039 (0%)

MJ:CNX $0.225 (40.63%)

MJNA $0.024 (4.35%)

MNTR $0.205 (2.24%)

MRRCF $0.013 (4.69%)

MWM:CNX $0.050 (-9.09%)

MYM:CNX $0.075 (0%)

MYMMF $0.057 (-0.38%)

NCNNF $0.270 (0%)

NDVAF $0.214 (-6.74%)

NGW:CNX $0.130 (-13.33%)

NRXCF $0.021 (0%)

NSPDF $0.059 (9.24%)

NTEC $0.560 (5.64%)

NVTQF $0.127 (0%)

NWKRF $0.424 (0%)

NXGWF $0.105 (-8.83%)

NXTTF $0.390 (13.27%)

ORHOF $4.050 (0%)

OWCP $0.065 (8.33%)

PHGI:CNX $0.500 (1.01%)

PHGRF $0.385 (1.45%)

PHVAF $0.094 (-5.14%)

PILL:CNX $0.480 (0%)

PKG:CNX $0.120 (9.09%)

PLPRF $1.145 (-3.8%)

PLUS:CNX $1.500 (-1.96%)

PMCB $0.047 (-2.08%)

PNPL $0.210 (0%)

POTN $0.033 (10%)

PRCNF $0.060 (-8.27%)

PTNYF $0.086 (3.66%)

QCA:CNX $0.110 (0%)

RDDTF $0.273 (-2.45%)

RLLVF $0.029 (3.56%)

RMHB $0.041 (3.07%)

RQB:CNX $0.080 (23.08%)

RQHTF $0.406 (11.4%)

RVVQF $0.065 (78.04%)

SLNG:CNX $0.390 (2.63%)

SMG $111.650 (0.83%)

SNN:CNX $0.220 (-12%)

SNNVF $0.184 (-9.98%)

SOL:CNX $0.520 (9.47%)

SOLCF $0.387 (1.95%)

SPLIF $0.030 (-19.14%)

SPRWF $0.458 (8.27%)

SRNA $0.069 (-2%)

STEM:CNX $1.260 (-0.79%)

STMH $1.040 (6.12%)

SUN:CNX $0.230 (0%)

TBPMF $0.500 (12.87%)

TCAN:CNX $1.510 (-7.36%)

TCNAF $1.223 (-0.91%)

TER:CNX $3.150 (-1.25%)

TGEN $2.100 (0%)

TGIF:CNX $0.220 (2.33%)

TGIFF $0.165 (-3.51%)

THC:CNX $0.150 (0%)

THCBF $0.115 (-3.2%)

TLRY $20.970 (2.64%)

TOKI:CNX $0.040 (33.33%)

TRLFF $0.172 (42.15%)

TRPX $0.780 (-3.58%)

TRSSF $2.430 (-1.02%)

TRTC $0.203 (4.81%)

TURV $0.060 (-14.29%)

VBIO $0.060 (-4%)

VIDA:CNX $0.125 (0%)

VIN:CNX $0.020 (33.33%)

VPRB $0.040 (14%)

VRNDF $0.564 (3.12%)

VRT:CNX $0.140 (7.69%)

VRTHF $0.086 (-10.04%)

VVCIF $0.210 (10.16%)

WAYL:CNX $0.740 (0%)

WDDMF $0.620 (-5.05%)

WLDFF $0.184 (7.45%)

XXII $1.140 (0%)

ZDPY $0.226 (-12.97%)

ZYNE $5.700 (-5.32%)

Technical420 Site Search

Returned 12 result(s).

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that its exclusive manufacturing partner, Dalton Pharma Services ("Dalton"), has received a three-year renewal and license…

Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the"Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce that it has appointed Michael J. Willner, Esq. as Business Advisor to the Company. Mr. Willner has been…

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately. Mr. Stott is…

Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the production of pharmaceutical cannabidiol ("CBD") products and in the development of innovative cannabidiol medicines for heart disease, commented on Purisys, LLC's news release issued on November 21st which states that the U.S. Drug Enforcement Agency ("DEA") has removed their…

Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the production of pharmaceutical cannabidiol (CBD) products and in the development of innovative cannabidiol medicines for heart disease, is pleased to announce the formation of the Clinical Steering Committee ("CSC") for a Phase 2 international trial in acute myocarditis using…

3 Canadian Cannabis Stocks Ready To Capitalize On Cannabis 2.0

One of the primary reasons for the lackluster sales of recreational cannabis in Canada is due to the availability of product (or lack thereof). We believe that the Canadian recreational cannabis market is barely in the first inning of a major growth cycle and expect to see the market gain…

Cardiol Therapeutics Has A Major Near Term Catalyst Right Around The Corner With The Proposed Launch Of CardiolRx™

Last month, we published a report that highlighted Cardiol Therapeutics Inc. (CRDL.TO) (CRTPF) as a leading player in the global cannabidiol (CBD) market and this is an opportunity that we are excited about. Cardiol has been able to differentiate itself from the competition through the development of a proprietary nanotechology…

Cardiol Therapeutics Is Leveraging Cutting Edge Technology and World Class Partnerships To Disrupt The Multi-Billion Dollar CBD Market

As the summer season comes to a close, the cannabis sector is trending higher and this is something that we are watching. During the last quarter, the sector had been under pressure with several leading companies impacted by the decline. Although the weakness over the summer was concerning, we believe…

Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for heart disease, is pleased to announce that the Company is planning an international clinical trial in acute myocarditis utilizing its CardiolRx CBD formulation. CardiolRx is Cardiol's pure…

Cardiol Therapeutics Is Leveraging World Class Partners To Bring Pure Premium CBD To Market

On May 31, 2019, Noramco, a world-leading manufacturer of controlled substances and active pharmaceutical ingredients (APIs) for the pharmaceutical industry, presented testimony and answered questions at the Food and Drug Administration's (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing.  This presentation had significance as Noramco…

Older Posts »

Search Again